ARTICLE | Clinical News
TPX-100: Ph II data
January 13, 2017 8:27 PM UTC
Top-line data from a double-blind, U.S. Phase II trial in 115 patients with mild to moderate patella-femoral OA in both knees showed that once-weekly intra-articular injections of TPX-100 for 4 weeks ...
BCIQ Company Profiles